Sarepta Therapeutics Inc (NASDAQ: SRPT) is 46.67% higher on its value in year-to-date trading and has touched a low of $55.25 and a high of $173.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SRPT stock was last observed hovering at around $143.45 in the last trading session, with the day’s loss setting it -2.02%.
Currently trading at $141.43, the stock is 1.76% and -0.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing -1.41% at the moment leaves the stock 16.52% off its SMA200. SRPT registered 24.40% gain for a year compared to 6-month gain of 4.93%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.13% loss in the last 1 month and extending the period to 3 months gives it a 10.23%, and is 6.07% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.63% over the week and 3.37% over the month.
Sarepta Therapeutics Inc (SRPT) has around 1314 employees, a market worth around $13.49B and $1.50B in sales. Current P/E ratio is 349.64 and Fwd P/E is 12.37. Profit margin for the company is 3.14%. Distance from 52-week low is 155.98% and -18.37% from its 52-week high. The company has generated returns on investments over the last 12 months (2.01%).
The EPS is expected to grow by 135.69% this year
667.0 institutions hold shares in Sarepta Therapeutics Inc (SRPT), with institutional investors hold 98.17% of the company’s shares. The shares outstanding are 93.73M, and float is at 89.46M with Short Float at 7.51%. Institutions hold 93.87% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 10.32 million shares valued at $1.63 billion. The investor’s holdings represent 10.9845 of the SRPT Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.04 million shares valued at $1.43 billion to account for 9.6133 of the shares outstanding. The other top investors are CAPITAL INTERNATIONAL INVESTORS which holds 4.32 million shares representing 4.5971 and valued at over $682.69 million, while STATE STREET CORP holds 4.4066 of the shares totaling 4.14 million with a market value of $654.4 million.
Sarepta Therapeutics Inc (SRPT) Insider Activity
The most recent transaction is an insider purchase by Chambers Michael Andrew, the company’s Director. SEC filings show that Chambers Michael Andrew bought 37,038 shares of the company’s common stock on Aug 16 ’24 at a price of $133.80 per share for a total of $4.96 million. Following the purchase, the insider now owns 0.28 million shares.
Sarepta Therapeutics Inc disclosed in a document filed with the SEC on Jun 25 ’24 that Brown Ryan Edward (EVP, General Counsel) sold a total of 38,957 shares of the company’s common stock. The trade occurred on Jun 25 ’24 and was made at $161.61 per share for $6.3 million. Following the transaction, the insider now directly holds 17129.0 shares of the SRPT stock.
Still, SEC filings show that on Jun 24 ’24, Arif Bilal (Chief Tech Ops Officer) disposed off 7,859 shares at an average price of $163.08 for $1.28 million. The insider now directly holds 21,261 shares of Sarepta Therapeutics Inc (SRPT).
